Oestrogen receptors and breast cancer.
作者信息
Elledge R M, Osborne C K
出版信息
BMJ. 1997 Jun 28;314(7098):1843-4. doi: 10.1136/bmj.314.7098.1843.
Abstract
摘要
相似文献
1
Oestrogen receptors and breast cancer.雌激素受体与乳腺癌
BMJ. 1997 Jun 28;314(7098):1843-4. doi: 10.1136/bmj.314.7098.1843.
2
Lymph-node-negative oestrogen-receptor-positive breast cancer.淋巴结阴性雌激素受体阳性乳腺癌
Lancet. 2004;364(9437):820-1. doi: 10.1016/S0140-6736(04)16994-8.
3
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.淋巴结阴性、雌激素受体阳性乳腺癌的治疗：国家外科辅助乳腺和肠道项目随机临床试验的长期结果
Lancet. 2004;364(9437):858-68. doi: 10.1016/S0140-6736(04)16981-X.
4
Mechanisms of tamoxifen resistance.他莫昔芬耐药的机制。
Endocr Relat Cancer. 2004 Dec;11(4):643-58. doi: 10.1677/erc.1.00776.
5
[Effects and mechanism of action of antiestrogens in breast cancer].[抗雌激素在乳腺癌中的作用及作用机制]
Pathol Biol (Paris). 1983 Nov;31(9):775-81.
6
Tamoxifen therapy--long-term results and complications.他莫昔芬治疗——长期结果与并发症
Adv Surg. 1996;29:263-9.
7
Solving the puzzle of hormone-dependent breast cancer.破解激素依赖性乳腺癌之谜。
Trans Am Clin Climatol Assoc. 1992;103:164-75.
8
Estrogen receptors and anti-estrogen therapies.雌激素受体与抗雌激素疗法。
Cancer Treat Res. 2004;119:271-92. doi: 10.1007/1-4020-7847-1_13.
9
New antiestrogen shows promise in ER-positive breast cancers.
Oncology (Williston Park). 1994 Aug;8(8):58.
10
Tamoxifen and breast conservation: do we still need radiotherapy?他莫昔芬与保乳手术：我们仍需要放疗吗？
Cancer. 1998 Jun 1;82(11):2090-2. doi: 10.1002/(sici)1097-0142(19980601)82:11<2090::aid-cncr2>3.0.co;2-#.
引用本文的文献
1
Opportunities and challenges of implementing Pharmacogenomics in cancer drug development.在癌症药物研发中实施药物基因组学的机遇与挑战。
Cancer Drug Resist. 2019 Mar 19;2(1):43-52. doi: 10.20517/cdr.2018.22. eCollection 2019.
2
Suppressed estrogen supply extra-ovarian progesterone receptor membrane component 1 in menopause.绝经时雌激素供应受抑制导致卵巢外孕激素受体膜成分1增加。 （注：此翻译可能因原英文表述在逻辑上不太清晰准确，翻译仅供参考，原英文可能需要进一步明确其确切含义以获得更精准译文）
J Biomed Res. 2021 Jan 29;35(3):228-237. doi: 10.7555/JBR.35.20200172.
3
Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors.基于综合自动化线性相互作用能的多种细胞色素P450芳香酶抑制剂结合亲和力预测
J Chem Inf Model. 2017 Sep 25;57(9):2294-2308. doi: 10.1021/acs.jcim.7b00222. Epub 2017 Aug 23.
4
Understanding the mechanisms of aromatase inhibitor resistance.了解芳香化酶抑制剂耐药的机制。
Breast Cancer Res. 2012 Jan 19;14(1):201. doi: 10.1186/bcr2931.
5
Rhein induces apoptosis in human breast cancer cells.利凡诺诱导人乳腺癌细胞凋亡。
Evid Based Complement Alternat Med. 2012;2012:952504. doi: 10.1155/2012/952504. Epub 2011 Oct 5.
6
The changing role of pathology in breast cancer diagnosis and treatment.病理学在乳腺癌诊断和治疗中的角色变化。
Pathobiology. 2011;78(2):99-114. doi: 10.1159/000292644. Epub 2011 Jun 14.
7
PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer.PDEF 和 PDEF 诱导蛋白作为乳腺癌 T 细胞和抗体介导免疫治疗的候选肿瘤抗原。
Immunol Res. 2010 Mar;46(1-3):206-15. doi: 10.1007/s12026-009-8129-2.
8
Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer.细胞系作为乳腺癌中ERBB2扩增和表达检测质量控制的候选参考物质。
Clin Chem. 2009 Jul;55(7):1307-15. doi: 10.1373/clinchem.2008.120576. Epub 2009 May 14.
9
Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.前列腺源性Ets因子的表达特征支持其在乳腺癌和前列腺癌进展中的作用。
Hum Pathol. 2007 Nov;38(11):1628-38. doi: 10.1016/j.humpath.2007.03.010. Epub 2007 May 22.
10
Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.7016例乳腺癌免疫组化分析中雌激素和孕激素受体阳性率：与患者年龄、检测敏感性、阈值及乳腺钼靶筛查的相关性
J Clin Pathol. 2000 Sep;53(9):688-96. doi: 10.1136/jcp.53.9.688.
Zotero 插件